GlassScriptPhysician profile
Aun A Munis
NPI 1659715993
$7,943.55
in general payments reported to CMS, 2019-2025
25 companies · $2,657 in 2025
The $2,657 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,185 · 2020: $312 · 2021: $714 · 2022: $799 · 2023: $1,087 · 2024: $1,189 · 2025: $2,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,863 · Education: $70.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,863.46 |
| Education | $70.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $1,769.84 | 2025 | Rapiblyk |
| Csl Behring | $611.70 | 2019-2025 | Kcentra |
| Janssen Pharmaceuticals, INC | $572.64 | 2019-2023 | Xarelto |
| Pfizer INC. | $550.46 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $520.25 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $500.32 | 2019-2025 | Eliquis, Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $473.50 | 2019-2025 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $397.83 | 2022-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $321.21 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $309.04 | 2019-2024 | Dificid, Zerbaxa |
| Astellas Pharma US INC | $279.88 | 2019-2022 | |
| Vifor Pharma, INC. | $277.99 | 2019-2023 | Veltassa |
| Novartis Pharmaceuticals Corporation | $266.25 | 2019-2023 | |
| Ferring Pharmaceuticals INC. | $245.02 | 2023-2025 | Rebyota |
| Abbvie INC. | $217.22 | 2021-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $193.17 | 2022-2025 | Fetroja |
| Paratek Pharmaceuticals, INC. | $93.39 | 2019-2024 | Nuzyra |
| Aimmune Therapeutics, INC. | $81.11 | 2025 | Vowst |
| Vertex Pharmaceuticals Incorporated | $63.96 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $55.69 | 2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $44.56 | 2019 | |
| Melinta Therapeutics, LLC | $34.53 | 2024-2025 | Rezzayo, Kimyrsa |
| Insmed, INC. | $26.15 | 2023 | Arikayce |
| Novo Nordisk INC | $22.47 | 2019 | |
| Mylan Specialty L.P. | $15.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aun Munis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.